Researchers Karijn Suijkerbuijk

Karijn Suijkerbuijk

Full Professor

Strategic program(s):

Biography

Karijn Suijkerbuijk is a translational medical oncologist with special interest in melanoma and immunotherapy. During her PhD, she performed research on tumor epigenetics in breast cancer in the lab of Professor Saraswati Sukumar at the Sidney Kimmel Cancer Center at Johns Hopkins University. Dr. Suijkerbuijk currently participates in multiple phase II and III clinical trials on immune checkpoint inhibitors. She published papers in Oncogene, Annals of Oncology and JNCI, received research grants from KWF and NWO and was awarded an ASCO Merit Award. Her current research focuses on clinical and immunological parameters assoaciated with immune related adverse events during checkpoint inhibition and clinicopathological factors associated with checkpoint inhibitor response.

Strategic program(s):

Contact

ksuijke2@umcutrecht.nl

Pure profile

Research groups

Molecular and cellular host-microbiota interactions

Research aim

Our research aims to unravel how the products from pathogenic and beneficial bacterial species within the intestinal microbiota contribute to human health and disease.

Go to group

Immunotherapy in solid tumors

Research aim

Our research aims at accomplishing cure and good quality of life for more and more patients with metastatic cancer by: - AI-based early identification of (non-)responders to current immunotherapy - new immunotherapies for non-responders - developing strategies to treat immunotherapy toxicity without compromising efficacy

Go to group

Recent publications

All publications

Resilience in advanced cancer patients who obtain a long-term response to immunotherapy or targeted therapy Laura C Zwanenburg, Eeske van Roekel, Karijn P M Suijkerbuijk, José J Koldenhof, Olga C J Schuurbiers-Siebers, Janneke van der Stap, Marije L van der Lee, Melanie P J Schellekens
Annals of Behavioral Medicine, 2025, vol. 59

The Co-Creation of a Psychosocial Support Website for Advanced Cancer Patients Obtaining a Long-Term Response to Immunotherapy or Targeted Therapy Laura C Zwanenburg, Marije L van der Lee, José J Koldenhof, Janneke van der Stap, Karijn P M Suijkerbuijk, Melanie P J Schellekens
Current oncology (Toronto, Ont.), 2025, vol. 32

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases M Bloem, K P M Suijkerbuijk, M J B Aarts, F W P J van den Berkmortel, C U Blank, W A M Blokx, M J Boers-Sonderen, C D M Boreel, J W B de Groot, J B A G Haanen, G A P Hospers, E Kapiteijn, O J van Not, D Piersma, B Rikhof, A M Stevense-den Boer, A A M van der Veldt, G Vreugdenhil, M W J M Wouters, A J M van den Eertwegh
European Journal of Cancer, 2025, vol. 223

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy E J van Dijk, H H Nienhuis, A J M van den Eertwegh, M J Boers-Sonderen, M Bloem, A M Kamphuis, M M Ros, C Bos, M J B Aarts, F W P J van den Berkmortel, C U Blank, W A M Blokx, J W B de Groot, G A P Hospers, D Piersma, R S van Rijn, A M Stevense-den Boer, G Vreugdenhil, M W J M Wouters, E Kapiteijn, J B Haanen, A A M van der Veldt, K P M Suijkerbuijk
British Journal of Cancer, 2025, vol. 133, p.66–75

Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma Saskia de Groot, Hedwig M Blommestein, Brenda Leeneman, Carin A Uyl-de Groot, John B A G Haanen, Michel W J M Wouters, Maureen J B Aarts, Franchette W P J van den Berkmortel, Willeke A M Blokx, Marye J Boers-Sonderen, Alfons J M van den Eertwegh, Jan Willem B de Groot, Geke A P Hospers, Ellen Kapiteijn, Olivier J van Not, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Pieter H M van Baal
Medical Decision Making, 2025, vol. 45, p.302-317

Clinical outcomes and genomic profiles of MAP2K1-mutated primary cutaneous melanocytic tumours Chiel F Ebbelaar, Anne M L Jansen, Leonie C M Speet, Frans Schutgens, Sietske Zoetemeyer, Anne-Marie Cleton-Jansen, Marijke R van Dijk, Gerben E Breimer, Lourens T Bloem, Wendy W J de Leng, Remco van Doorn, Karijn P M Suijkerbuijk, Anne M R Schrader, Willeke A M Blokx,
EBioMedicine, 2025, vol. 114

Fellowships & Awards

2007  Research year for residents (UU2007-3977) KWF
2008  Translational grant KWF (UU-2008-4217
2008  AGIKO stipend, ZonMW
2008  ASCO Merit Award

2018 ZonMW goed gebruik geneesmiddelen

External positions

research funding Genmab - AI onderzoekssamenwerking in Health Holland project dat door Genmab financieel wordt ondersteund - Genmab

ESMO melanoma faculty - expertise melanoom - European Society for Medical Oncology

Lid real world data working group ESMO - onderzoek patientcohorten - European Society for Medical Oncology

Lid wetenschappelijke adviesraad - ervaring onderzoek - Maarten van der Weijden foundation

Adviesraad stichting melanoom (sinds 2019) - Vanuit expertise als melanoombehandelaar - Stichting melanoom

Lid Data Safety Monitoring Committee CHOPIN studie (vanaf 2020; studie gesponsord door BMS) - onderzoekservaring immuuntherapie - LUMC

Voorzitter wetenschappelijke commissie - Kwaliteitsverbetering en onderzoek op het gebied van melanoomzorg - Dutch Melanoma Treatment Registry (DICA)

Adviesgroep kanker in de zwangerschap - Expertise melanoom en immuuntherapie - Adviesgroep kanker in de zwangerschap

Organisatie/voorzitter jaarlijks immuno-oncologie symposium - expertise en onderzoek immuunoncologie - Immuno-oncologie symposium

Bestuurslid Tumorfocusgroep melanoom - expertise melanoom - Tumorfocusgroep melanoom

medisch expert bij melanoom nascholing en congresjournaal ASCO/ESMO - expertise melanoom - Medtalks